GlassScriptPhysician profile
Katherine Williams
NPI 1003443003
$3,821.02
in general payments reported to CMS, 2019-2025
34 companies · $1,264 in 2025
The $1,264 reported for 2025 was more than what 84% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $30.20 · 2022: $162 · 2023: $585 · 2024: $1,780 · 2025: $1,264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,629.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,628.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $575.35 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $495.30 | 2023-2025 | |
| Lilly USA, LLC | $443.69 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $218.15 | 2023-2025 | Jardiance |
| Glaxosmithkline, LLC. | $192.98 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $185.39 | 2024-2025 | |
| Biotronik Nro, INC. | $182.52 | 2024 | Prospera |
| Astrazeneca Pharmaceuticals LP | $168.47 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Medtronic, INC. | $155.85 | 2023-2025 | Progrip, Intellis Adaptivestim, Inceptiv |
| Takeda Pharmaceuticals U.S.A., INC. | $148.97 | 2021-2024 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $111.85 | 2025 | |
| Idorsia Pharmaceuticals US INC | $86.14 | 2023-2024 | Quviviq |
| Viiv Healthcare Company | $78.77 | 2024-2025 | Apretude |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $70.91 | 2024-2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.44 | 2024-2025 | Xifaxan |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $66.31 | 2023-2025 | Rexulti |
| Sumitomo Pharma America, INC. | $62.71 | 2023-2024 | Gemtesa |
| Exact Sciences Corporation | $59.42 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $55.52 | 2024-2025 | Auvelity, Symbravo |
| Phathom Pharmaceuticals, INC. | $52.45 | 2025 | Voquezna |
| Merck Sharp & Dohme LLC | $49.64 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Novartis Pharmaceuticals Corporation | $32.20 | 2022-2025 | |
| Edwards Lifesciences Corporation | $31.85 | 2024-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Amgen INC. | $30.35 | 2024 | Evenity, Prolia, Repatha |
| Sanofi Pasteur INC. | $26.79 | 2025 | |
| Lundbeck LLC | $25.59 | 2024 | Rexulti |
| Actelion Pharmaceuticals US, INC. | $21.88 | 2024 | Opsumit, Uptravi |
| Bausch Health US, LLC | $20.43 | 2024 | Aplenzin, Wellbutrin |
| Ars Pharmaceuticals Operations, INC. | $20.02 | 2025 | Neffy |
| Abiomed | $19.08 | 2024 | Impella |
| Insightec,INC | $18.40 | 2025 | Exablate |
| Daiichi Sankyo INC. | $15.00 | 2025 | Injectafer |
| Neos Therapeutics, LP | $14.97 | 2024 | Adzenys Xr-Odt |
| Currax Pharmaceuticals LLC | $14.63 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.